文献速递免疫规划传染病防控与疫情报告

西班牙女孩乳头瘤病毒疫苗接种与吉兰-巴雷综合征的队列研究

Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain.
PubMed 文献 · Vaccine · 2021-06-24

基于西班牙初级保健数据库BIFAP的队列研究,纳入2007-2016年9-18岁女孩388849人(154255人接种),评估HPV疫苗接种后吉兰-巴雷综合征风险。接种后任意时间调整HR为1.24(95%CI 0.19-8.00),仅能排除相对于未接种8倍以上的风险增加。

要点

  • 接种后任意时间GBS调整HR为1.24(95%CI 0.19-8.00),无统计学意义。
  • 所有3例接种后GBS均发生在90天风险窗口之后,HR为1.77(95%CI 0.25-12.54)。
  • 研究把握度不足,仅能排除相对未接种8倍以上的风险增加。

核心结论

  • HPV疫苗接种后GBS发病率与既往年轻人报告范围一致,但研究把握度不足以精确量化罕见风险。
  • 仅能排除相对于未接种8倍以上的GBS风险增加。

研究设计与样本

  • 基于西班牙初级保健数据库BIFAP的队列研究。
  • 纳入2007-2016年9-18岁无GBS且未接种HPV疫苗的女孩388849人,其中154255人接种。
  • 随访至GBS诊断,采用时变暴露和混杂因素分析。

主要发现

  • 非暴露期确认GBS 6例,发病率为5.83/百万 person-years(95%CI 2.62-12.97)。
  • 接种后任意时间确认GBS 3例,发病率为7.87/百万 person-years(95%CI 2.54-24.39)。
  • 接种后任意时间调整HR为1.24(95%CI 0.19-8.00)。
  • 3例均发生在90天风险窗口之后,暴露后时期相比非暴露期HR为1.77(95%CI 0.25-12.54)。
  • 风险窗口内零例,无法估计HR。

临床怎么用

  • 现有数据不支持HPV疫苗接种后GBS风险显著增加,但研究把握度有限。
  • 监测中应关注接种后90天以后发生的GBS事件。

局限性

  • GBS极罕见,队列研究把握度不足,无法精确估计相对风险。
  • 仅能排除8倍以上的风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies of the association of Guillain-Barré Syndrome (GBS) with papillomavirus vaccination (HPVv; scheduled from 2007) have provided contradicting results, probably due to the low frequency of this disease. We aimed at estimating that risk relative to non-vaccination among girls, by using the Spanish Primary Care Database for Pharmacoepidemiological Research (BIFAP). METHODS: A cohort study of girls aged 9-18 years during 2007-2016 free of GBS or HPVv was selected and followed up to GBS diagnosis. Follow-up time was divided by time-varying HPVv exposure and confounders. Crude Incidence rates (IR per 1,000,000 person-years (py)) and adjusted Hazard Ratios (HR) of GBS were estimated anytime after vaccination compared to non-exposed periods. HRs were also estimated for the first 90 days after HPVv (risk-window) and thereafter. RESULTS: Out of 388,849 girls, of which 154,255 were vaccinated, 6 'confirmed' GBS cases occurred during non-exposure periods (IR of 5.83 per million person-years; 95% CI: 2.62-12.97) and 3 'confirmed' cases anytime after vaccination (IR of 7.87; 95% CI: 2.54-24.39). The resulting adjusted HR anytime after vaccination was 1.24 (95% CI: 0.19-8.00). All three cases occurred after the risk window of 90 days with an HR of 1.77 (95% CI: 0.25-12.54) for post-exposure periods as compared with non-exposure. Since zero cases occurred during the risk window, no HR could be estimated for exposed periods. CONCLUSIONS: Incidences of GBS were in line with the range previously reported for young people, supporting the potential of BIFAP for performing studies on GBS. However, a lack of power may be present for quantifying the relative risk of such a rare disease after the vaccination among the study cohort, where we can only exclude an increased risk of 8-times relative to no vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Martín-Merino E, Castillo-Cano B, Martín-Perez M, et al. Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain. Vaccine. 2021. PMID: 34175126. doi:10.1016/j.vaccine.2021.06.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。